<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026388</url>
  </required_header>
  <id_info>
    <org_study_id>11-005413</org_study_id>
    <nct_id>NCT02026388</nct_id>
  </id_info>
  <brief_title>Rare Kidney Stone Consortium Biobank</brief_title>
  <official_title>Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to obtain samples from patients with primary hyperoxaluria,&#xD;
      cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from&#xD;
      their family members, for use in future research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic samples will be stored in the biobank from well characterized patients with primary&#xD;
      hyperoxaluria, cystinuria, APRT deficiency, and Dent disease, and from their family members,&#xD;
      for use in future research. This will help to advance our understanding of disease expression&#xD;
      and the factors associated with kidney injury in these four diseases with the overall goal of&#xD;
      developing new treatments to preserve kidney function and reduce nephrocalcinosis and stone&#xD;
      formation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of samples stored in tissue bank</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <condition>Dent Disease</condition>
  <condition>APRT Deficiency</condition>
  <condition>Cystinuria</condition>
  <arm_group>
    <arm_group_label>Primary Hyperoxaluria</arm_group_label>
    <description>Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dent Disease</arm_group_label>
    <description>Diagnosis of Dent Disease, or a family member of someone with this diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystinuria</arm_group_label>
    <description>Diagnosis of Cystinuria, or a family member of someone with this diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APRT deficiency</arm_group_label>
    <description>Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, blood and tissue samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with a confirmed Diagnosis of Primary Hyperoxaluria, Dent Disease, APRT&#xD;
        deficiency or Cystinuria. Family members of individuals with these four diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria:&#xD;
&#xD;
               1. Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below&#xD;
                  the normal reference range confirming PH type 1 OR Liver biopsy documenting&#xD;
                  glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal&#xD;
                  reference range confirming PH type 2&#xD;
&#xD;
               2. Molecular genetic analysis (DNA testing) confirming mutations known to cause PH&#xD;
                  type 1, PH type 2, or PH type 3&#xD;
&#xD;
               3. Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (&gt;70 mg/1.73&#xD;
                  m2/day) in the absence of a identifiable causes of secondary hyperoxaluria,&#xD;
                  including gastrointestinal disease known to cause enteric hyperoxaluria&#xD;
&#xD;
               4. A patient in end stage kidney failure, in whom neither a liver biopsy nor&#xD;
                  mutational analysis are available must have: (a) A plasma oxalate concentration&#xD;
                  of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate&#xD;
                  deposits OR (b) Evidence of systemic oxalosis&#xD;
&#xD;
               5. Participants in the previous protocol &quot;Tissue Bank of Urine, Blood, and Tissue&#xD;
                  Samples Collected from the Patients with Primary Hyperoxaluria&quot; 'Mayo IRB #'&#xD;
                  #80-04. They have already consented to bank their samples and that consent will&#xD;
                  serve to enroll them in this study.&#xD;
&#xD;
          -  Diagnosis of Dent disease meeting one or more of the following criteria:&#xD;
&#xD;
               1. Identified mutation of the gene that encodes for chloride exchange transporter 5&#xD;
                  (CLCN5)&#xD;
&#xD;
               2. Low molecular weight proteinuria and hypercalciuria&#xD;
&#xD;
               3. Low molecular weight proteinuria and nephrocalcinosis&#xD;
&#xD;
          -  Diagnosis of APRT disease meeting one or more of the following criteria:&#xD;
&#xD;
               1. Suspected dihydroxyadeninuria and absent APRT enzyme activity measured in red&#xD;
                  blood cells (RBCs).&#xD;
&#xD;
               2. Homozygosity, or compound heterozygosity, for known disease-causing APRT&#xD;
                  mutations.&#xD;
&#xD;
               3. Passage of dihydroxyadenine stones (confirmed with stone analysis).&#xD;
&#xD;
          -  Diagnosis of Cystinuria meeting one or more of the following criteria:&#xD;
&#xD;
               1. Stone analysis demonstrating that the stone contains cystine&#xD;
&#xD;
               2. Increased urinary cystine excretion (&gt;250 mg/gm creatinine)&#xD;
&#xD;
          -  Relative of someone with confirmed primary hyperoxaluria, Dent disease, APRT&#xD;
             deficiency (also known as dihydroxyadeninuria), or cystinuria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stone formers who do not meet the inclusion criteria for primary hyperoxaluria,&#xD;
             cystinuria, Dent disease, or APRT deficiency.&#xD;
&#xD;
          2. Unwilling or unable to provide consent/assent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Lieske, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia M Meek</last_name>
    <phone>507-255-4347</phone>
    <email>meek.alicia@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara M Seide</last_name>
    <phone>507-255-0387</phone>
    <email>seide.barbara@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia M Meek</last_name>
      <phone>507-255-4347</phone>
      <email>meek.alicia@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara M Seide</last_name>
      <phone>507-255-0387</phone>
      <email>seide.barbara@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John C Lieske, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rarekidneystones.org/</url>
    <description>Rare Kidney Stone Consortium</description>
  </link>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PH</keyword>
  <keyword>primary hyperoxaluria</keyword>
  <keyword>hyperoxaluria</keyword>
  <keyword>primary oxalosis</keyword>
  <keyword>Primary Hyperoxaluria Type 1</keyword>
  <keyword>Primary Hyperoxaluria Type 2</keyword>
  <keyword>Primary Hyperoxaluria Type 3</keyword>
  <keyword>Dent</keyword>
  <keyword>Dents</keyword>
  <keyword>Dent Disease</keyword>
  <keyword>Dent 1</keyword>
  <keyword>Dent 2</keyword>
  <keyword>Cystinuria</keyword>
  <keyword>APRT</keyword>
  <keyword>APRT deficiency</keyword>
  <keyword>Biobank</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
    <mesh_term>Cystinuria</mesh_term>
    <mesh_term>Dent Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Biospecimens repository only. No individual data available to share.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

